Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells

Chara Stavraka(King's College London), Sarah P. Blagden(Churchill Hospital), Thezenas M-L., Laki Buluwela(The London College), Manuela Mura(Ovarian Cancer Action), James Chettle(University of Oxford), Susan Maghami, R. Fischer, Brittelle E. Kessler
Spiral (Imperial College London)
March 14, 2017
10.1158/1538­7445
Cited by 1

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168